FDA Reviews MDMA Therapy for PTSD, Citing Health Risks and Study Flaws
Posted inAlternative and Complementary Medicine Clinical Trials Depression (Mental) Drug Abuse and Traffic Drug Enforcement Administration Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration MAPS Public Benefit Corp Mental Health and Disorders Placebos Post-Traumatic Stress Disorder Psychedelic and Hallucinogenic Drugs Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

FDA Reviews MDMA Therapy for PTSD, Citing Health Risks and Study Flaws

The agency’s staff analysis suggests that approval of the illegal drug known as Ecstasy for treatment of PTSD is far from certain, with advisers meeting next week to consider the proposed therapy.
F.D.A. Approves New Treatment for Early Alzheimer’s
Posted inBiogen Inc Centers for Medicare and Medicaid Services Drugs (Pharmaceuticals) Eisai Co Ltd Food and Drug Administration Labeling and Labels (Product) Medicare New England Journal of Medicine Placebos United States

F.D.A. Approves New Treatment for Early Alzheimer’s

The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.